Talha K, PharmD, BCOP
@TalhaKhanRx
Followers
163
Following
1K
Media
4
Statuses
117
Heme/Onc PharmD at Northwestern. STLCOP alumni. PGY1 & PGY2 Onc at Northwestern. Views are my own.
Chicago, IL
Joined April 2021
Lunch away from convention at #ASH24 to discuss leukemia w current and former @NorthwesternMed @LurieCancer colleagues. #HummusIsMyHappyFood @ASH_hematology @yasminabaza1 @dralainmina @TalhaKhanRx @SaraSmallMD1 💜
6
4
42
Today marks my last time rounding on the leukemia service. My heartfelt thanks to everyone at NM for all the love & encouragement over the years. You will always have a piece of my heart. @jaltmanmd @yasminabaza1 @Irumkhan_hem @NorthwesternMed @LurieCancer
7
3
43
Weekend review 1/11 Outcome of MDS progressing on hypomethylating agent has dismal OS in the range of 6-9 months; worse with #TP53m No approved therapy for this poor prognostic disease. https://t.co/tngc8IRXFB 👇🏽 🧵 on prospective and retrospective studies.
4
9
42
HMA/Ven for Patients ≥ 75 year old with AML - real world multi-center analysis. Congrats @yasminabaza1 for all your hard works on this! @jaltmanmd @LurieCancer @NorthwesternMed
https://t.co/S3c8aUALkL
1
6
21
Ven Less is More: Ven 14 days non-inferior to 28 days in newly-diagnosed acute myeloid leukemia. https://t.co/Cv0hUxVKsM
0
26
76
Today was one of those days that our #PharmDs went above & beyond to care for our #AML pts. Actually, that happens every day….Thank you @TalhaKhanRx @MagdaDankowska and team for today and all the days I forget to share my 💜 and appreciation. @LurieCancer @NorthwesternMed
4
3
47
Our manuscript re #Aspacytarabine for txt of pts w #AML unfit for intensive chemo was just published in @BloodAdvances! @tinabhatnagar01 @SelinaLugerMD @groboz @vamkota @yasminabaza1 @LFlaishon @RuthBenYakar @LurieCancer and so many colleagues.
ashpublications.org
Aspacytarabine enables delivery of high-dose cytarabine to unfit patients without the prohibitive cerebellar and gastrointestinal toxicities.Aspacytarabine
7
21
64
Cilta-cel box warning updated to include MDS/AML in 10% (10/97) of patients following treatment in the CARTITUDE-1 study. https://t.co/esZaayvMOP
0
0
2
A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of @EshanaShahMD for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients @UICancerCenter and @LurieCancer
2
8
28
Starting out ASH with running into our colleague and Leukemia guru @MartinTallman @yasminabaza1 @MagdaDankowska @ASH_hematology @NorthwesternMed
2
1
17
Weekend reading 📖 #ASH23, few selected #ALL abstracts to watch for at this year ASH @ASH_hematology #leusm 🧵 👇🏽
3
13
64
ASH23 Practice Changing LBAs are out! 1)Perseus trial primary results. (dex,VRd over VRd) #myeloma 2)BMT-CTN1507: HaploBMT in adults with severe SCD. Curative therapy for SCD. Widely available in US. Cure rates ~90%. 10x less expensive than gene therapy/editing. #sicklecell
1
14
43
A pleasure to share this work from @Dr_KatLewis et al re: high-dose methotrexate as CNS Prophylaxis in High-Risk B-Cell lymphoma just out in @JCO_ASCO HUGE international effort spanning years: thanks ++ to all collaborators #lymSM #CNSprophylaxis
https://t.co/yfQFsZO0pd
ascopubs.org
PURPOSECNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was...
3
6
55
How I Treat Post-Transplant Lymphoproliferative Disorder https://t.co/OZGX2MpXSw
@jenamengual @columbiacancer @nyphospital
ashpublications.org
Amengual and Pro present their approach to posttransplant lymphoproliferative disease (PTLD), complicating solid organ transplant and hematopoietic cell tr
1
22
80
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma | NEJM. CARTITUDE-4 #mmsm #bmtsm
nejm.org
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We i...
1
15
30
QuANTUM-First trial that led to approval of Quizartinib https://t.co/zyrNsxfPzM Key differences compared to RATIFY: 1. Patient were older up to 75 y compared to 60 y; more, high-risk, sAML 3. Pts with FLT3 TID only 4. Quizartinib maint. up to 3 y compared 👉 1 y in RATIFY
1
10
31
0
3
26
So here are the curves for SWOG S1836 - AAVD v AVD-nivo. 1 y PFS 94% N-AVD vs 86%. Impressive result but 1y PFS is a pretty early endpoint. Very interesting to see if the differences hold. Safety looking v good for AVD-N.
4
17
63
Thank you @TalhaKhanRx @MagdaDankowska @DWRx @n1coleRx @KbeePharmd and crew for always having our backs and putting patients first. Would not be safe to care for #AMLsm patients without you. @yasminabaza1 💜
did someone really compare pharmacists to charlatans? I have seen pharmacists save lives, prevent dosing errors, guide complicated medication administration, and do math (WITH DECIMAL POINTS) while everyone is yelling...all at the same time pharmacists are absolutely incredible
0
2
8